Reports Q3 revenue $1.02B, consensus $987.2M. The company said, “”In the third quarter we made advances that underscore the potential of our late-stage portfolio; Epcoritamab moved closer to being available to patients in earlier lines of therapy for follicular lymphoma and Rina-S was granted Breakthrough Therapy Designation in advanced endometrial cancer. With robust development plans for both epcoritamab and Rina-S and with Tivdak now available for prescribing in Germany – our first commercial entry into a European market – we continue to execute on our strategic imperatives to accelerate our late-stage pipeline and maximize our approved medicines to reach more patients.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment
- Genmab’s New Phase 3 Study: A Potential Game-Changer in Endometrial Cancer Treatment
- Genmab’s Phase 3 Study on Rina-S: A Potential Game-Changer for Ovarian Cancer Treatment
- Genmab’s GEN1057 Trial: A New Hope in Cancer Treatment?
- Pfizer and Genmab’s Tivdak Study: Ocular Side Effects Under the Microscope